Severe Asthma in SchoolAge Children Evaluation a

Authors: Andrea Coverstone Leonard B Bacharier Anne M Fitzpatrick

Publish Date: 2015/07/02

Volume: 15, Issue: 5, Pages: 20-

PDF Link

Abstract

Although the majority of children with asthma have a favorable clinical response to treatment with low to moderate doses of inhaled corticosteroids ICS a small subset of children have “severe” asthma characterized by ongoing symptoms and airway inflammation despite treatment with high doses of ICS and even oral corticosteroids Although there is symptom heterogeneity in the affected children children with severe asthma share the risk for adverse outcomes including recurrent and potentially lifethreatening exacerbations which contribute to substantial economic burden This article reviews current knowledge of severe asthma in schoolage children age 6–17 years with a focus on recent literature published after January 2012 Clinical management approaches for children with severe asthma are discussed as well as current phenotyping efforts and emerging phenotypicdirected therapies that may be of benefit for subpopulations of children with severe asthma in the futureLeonard B Bacharier reports consultancies from Aerocrine GlaxoSmithKline Genentech/Novartis Merck Schering Cephalon DBV Technologies and Teva Anne M Fitzpatrick reports consultancies from MedImmune Merck GlaxoSmithKline Genentech and Boehringer Ingelheim Andrea Coverstone declares no conflict of interest

Keywords: